CAPTRUST Financial Advisors
MRSN

CAPTRUST Financial Advisors’s Mersana Therapeutics MRSN Stock Holding History

CAPTRUST Financial Advisors’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1,670
Closed -$12.4K – 2677
2025
Q2 		$12.4K Buy
1,670
+425
+34% +$3.73K ﹤0.01% 2488
2025
Q1 		$10.7K Buy
+1,245
New +$19.2K ﹤0.01% 2336
2022
Q3 		– Sell
-9
Closed -$1K – 3273
2022
Q2 		$1K Sell
9
-2
-18% -$188 ﹤0.01% 4702
2022
Q1 		$1K Sell
11
-3
-21% -$350 ﹤0.01% 4717
2021
Q4 		$2K Sell
14
-3
-18% -$584 ﹤0.01% 4426
2021
Q3 		$4K Hold
17
– – ﹤0.01% 4044
2021
Q2 		$6K Hold
17
– – ﹤0.01% 3786
2021
Q1 		$7K Sell
17
-63
-79% -$30.6K ﹤0.01% 3602
2020
Q4 		$53K Buy
+80
New +$44.5K ﹤0.01% 1804

Other funds holding MRSN

NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
AV
Alamea Verwaltungs Edison, New Jersey $125M AUM 27.56% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

CAPTRUST Financial Advisors's MRSN Position: Q3 2025 in Review

CAPTRUST Financial Advisors sold out of Mersana Therapeutics (MRSN) in Q3 2025, closing a stake of 1,670 shares — an estimated $12.4K sold.

CAPTRUST Financial Advisors first reported a position in MRSN in Q4 2020 and held it in 9 quarters. The position peaked at $53K in Q4 2020. 49 funds tracked by Wall St. Rank hold MRSN as of Q3 2025.

  • CAPTRUST Financial Advisors reported no remaining Mersana Therapeutics position as of Q3 2025 after selling out during the quarter.
  • CAPTRUST Financial Advisors sold 1,670 Mersana Therapeutics shares in Q3 2025, an estimated $12.4K.
  • CAPTRUST Financial Advisors first reported a position in Mersana Therapeutics in Q4 2020 and held it in 9 quarters.
  • CAPTRUST Financial Advisors's Mersana Therapeutics position peaked at $53K in Q4 2020.
  • 49 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q3 2025.

Based on CAPTRUST Financial Advisors's 13F filing for Q3 2025, filed 19 Nov 2025.